报价延迟最少15分钟:2025/07/20 16:15 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.5 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-7.67/-3.32
|
|
企业价值
45.46M
|
| 资产负债 |
|
每股账面净值
6.25
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 16:15 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities. |
